CD80-Binding Peptide Sequences for Liposome Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on peptides that bind to the CD80 protein for immune regulation and drug delivery is limited, leading to stagnation in the development of effective drug delivery systems.
Innovation Solution
Development of novel peptides, specifically with amino acid sequences SEQ ID NO: 1 and SEQ ID NO: 2, which can bind to the CD80 protein and are used to modify drug carriers such as liposomes, enabling enhanced cellular uptake and drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional research approaches are used for peptide development, then existing knowledge on CD80 binding is maintained, but development stagnation occurs and no effective drug delivery systems are achieved
Solution Approach 1:
The patent applies parameter changes by systematically varying peptide sequence parameters (amino acid composition, length, and specific residues) to identify optimal binding sequences. The invention tested multiple peptide variants with different sequences and found that specific sequences (such as those containing certain amino acid patterns) achieve superior CD80 binding affinity, thereby resolving the contradiction between development productivity and binding reliability.
Solution Approach 2:
The patent employs the copying principle by using phage display technology to create a library of peptide copies that can be screened for binding activity. The phage display system allows rapid generation and testing of numerous peptide sequences, enabling efficient identification of effective binding peptides without requiring de novo design, thus accelerating drug delivery system development while ensuring binding effectiveness.
2Reliability
If peptide sequences are optimized for CD80 binding, then binding affinity is improved, but the complexity of peptide characterization and validation increases
Solution Approach 1:
The patent applies the intermediary principle by using phage display as a mediator between peptide sequence design and binding validation. The phage display system serves as an intermediary platform that allows systematic presentation of peptide sequences against CD80, enabling high-throughput screening and affinity measurement without requiring direct complex characterization of each peptide variant, thus reducing overall process complexity while maintaining high binding affinity selection.
3Productivity
If peptides are integrated onto drug carriers, then cellular uptake is enhanced, but the complexity of drug carrier modification and formulation increases
Solution Approach 1:
The patent applies segmentation by separating the peptide binding function from the drug carrier delivery function. The peptide sequences are designed and optimized independently for CD80 binding, while the drug carrier (such as liposomes or nanoparticles) is designed independently for delivery. The integration step is simplified by using standard conjugation methods to attach the peptide to the carrier surface, allowing each component to be optimized separately while achieving enhanced cellular uptake through the peptide-carrier composite.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel peptides facilitate increased cellular uptake of drug carriers, particularly liposomes, enhancing the efficiency of drug delivery systems.
Implementation Method 1
novel peptides that can bind to differentiation group 80
Data Source
AI summary
The present invention provides a novel peptide, usages thereof and pharmaceutical composition having the same. The novel peptide is a first peptide. The pharmaceutical composition comprises the novel peptide and drug carriers, each novel peptide is connected to the surface of the drug carrier by a linker. The amino acid sequence of the first peptide is shown in SEQ ID NO: 1. The first peptide can bind to CD80 protein, besides, the present invention proves that the novel peptide of the present invention achieves the efficiency of enhancing cell uptake.